Second-line bevacizumab plus FOLFOX in patients with metastatic colorectal cancer previously treated with adjuvant oxaliplatin-based chemotherapy.

被引：0
|
作者：
Chun, Sang Hoon
Kim, Jung Hoon
Kwag, Seung-Jin
Kang, Myoung Hee
Park, Ji-Ho
Lee, Gyeong-Won
Kang, Jung Hun
机构：
[1] Catholic Univ Korea, Bucheon St Marys Hosp, Dept Internal Med, Div Hematol Oncol, Bucheon Si, South Korea
[2] Gyeongsang Natl Univ Hosp, Dept Internal Med, Div Hematol Oncol, Jinju Si, South Korea
[3] Gyeongsang Natl Univ Hosp, Jinju Si, South Korea
[4] Gyeongsang Natl Univ, Sch Med, Jinju Si, South Korea
[5] Gyeongsang Natl Univ, Jinju Si, South Korea
[6] Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Div Hematol & Oncol,Dept Internal Med, Jinju, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
157
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [1] Bevacizumab Plus Irinotecan-Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens
    Yildiz, Ramazan
    Buyukberber, Suleyman
    Uner, Aytug
    Yamac, Deniz
    Coskun, Ugur
    Kaya, Ali Osman
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    CANCER INVESTIGATION, 2010, 28 (01) : 33 - 37
  • [2] Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimen
    Yildiz, R.
    Buyukberber, S.
    Uner, A.
    Yamac, D.
    Coskun, U.
    Kaya, A. O.
    Ozturk, B.
    Yaman, E.
    Benelkli, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 143 - 143
  • [3] Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer
    Beatty, Gregory L.
    Giantonio, Bruce J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (05) : 683 - 688
  • [4] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Hidekazu Kuramochi
    Masayuki Ando
    Michio Itabashi
    Go Nakajima
    Kazuyuki Kawakami
    Mie Hamano
    Eiichi Hirai
    Hajime Yokomizo
    Ryuji Okuyama
    Tatsuo Araida
    Kazuhiko Yoshimatsu
    Shingo Kameoka
    Kazuhiko Hayashi
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
  • [5] A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
    Nakajima, Go
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Lino, Takayuki
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER RESEARCH, 2016, 76
  • [6] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Nakajima, Go
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 579 - 585
  • [7] Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
    Gerger, Armin
    El-Khoueiry, Anthony
    Zhang, Wu
    Yang, Dongyun
    Singh, Harpreet
    Bohanes, Pierre
    Ning, Yan
    Winder, Thomas
    LaBonte, Melissa J.
    Wilson, Peter M.
    Benhaim, Leonor
    Paez, David
    El-Khoueiry, Rita
    Absenger, Gudrun
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2011, 17 (17) : 5783 - 5792
  • [8] Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer
    Shi, Sha
    Lu, Kemei
    Gao, Hui
    Sun, Huidong
    Li, Senlin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (09): : 1971 - 1977
  • [9] Chemotherapy efficacy in metastatic colorectal cancer (mCRC) patients treated with adjuvant or first-line FOLFOX-based chemotherapy.
    Samalin, Emmanuelle
    Tien Tuan Nguyen
    Thezenas, Simon
    Portales, Fabienne
    Mazard, Thibault
    Gourgou, Sophie
    Assenat, Eric
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
    Iwamoto, S.
    Takahashi, T.
    Tamagawa, H.
    Nakamura, M.
    Munemoto, Y.
    Kato, T.
    Hata, T.
    Denda, T.
    Morita, Y.
    Inukai, M.
    Kunieda, K.
    Nagata, N.
    Kurachi, K.
    Ina, K.
    Ooshiro, M.
    Shimoyama, T.
    Baba, H.
    Oba, K.
    Sakamoto, J.
    Mishima, H.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1427 - 1433
12345